Program

Timetable

Timetable

General Session

Special Lecture (co-sponsored by Annual meeting and Short course)

November 7 (Mon.) 18:00-19:00 1F Main Hall

  • ChairFumiyoshi Yamashita
    Graduate School of Pharmaceutical Sciences, Kyoto University

Contribution of Mass Spectrometry to Phamacokinetics

  • SpeakerKoichi Tanaka
    Shimadzu Corporation Mass Spectrometry Research Laboratory

Special Lecture

November 8 (Tue.) 9:00-10:00 1F Main Hall

  • ChairHideki Hirabayashi
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

From Invention, to Innovation

  • SpeakerTakanori Takebe
    Institute of Research, Tokyo Medical and Dental University /
    Center for Stem Cell and Organoid Medicine,
    Cincinnati Children's Hospital Medical Center

Keynote Lecture 1

November 8 (Tue.) 13:30-14:30 1F Main Hall

  • ChairShinji Iwasaki
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Towards Whole-body/organ Imaging with Single-cell Resolution

  • SpeakerHiroki R. Ueda
    Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo

Keynote Lecture 2

November 8 (Tue.) 14:30-15:30 1F Main Hall

  • ChairToshiya Moriwaki
    Pharmaceutical Development Division, Towa Pharmacetical CO.,LTD

Muse cell treatment: Next-generation medical revolution compatible with the 'body's natural repair systems'

  • SpeakerMari Dezawa
    Department of Stem Cell Biology and Histology,
    Tohoku University Graduate School of Medicine

Keynote Lecture 3

November 8 (Tue.) 15:30-16:00 1F Main Hall

  • ChairHiroshi Mizuuchi
    DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation

Astellas' Frontiers of Intelligence Drug Discovery

  • SpeakerKenji Tabata
    Discovery Intelligence, Appried Research & Operations,
    Astellas Pharma Inc.

JSSX President's Session

November 9 (Wed.) 16:15-17:30 Room A (3F 315)
*Satellite Room : Room B (3F 313+314), Room C (3F 311+312)

  • ChairFumiyoshi Yamashita
    Graduate School of Pharmaceutical Sciences, Kyoto University

Toward the Future of Pharmaceuticals in Society 5.0

  • SpeakerYuji Ikegaya
    Graduate School of Pharmaceutical Sciences,
    The University of Tokyo
<Panel discussion>
  • FacilitatorHideki Hirabayashi
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  • PanelistYuji Ikegaya
    Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • PanelistFumiyoshi Yamashita
    Graduate School of Pharmaceutical Sciences, Kyoto University
  • PanelistHiroshi Mizuuchi
    DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
  • PanelistShingo Sakamoto
    Shionogi & Co., Ltd.

Special Symposium 1

November 8 (Tue.) 10:00-12:00 1F Main Hall

The interface between Nobel Prize-winning technologies and pharmacokinetic research

  • ChairsSyunsuke Yamamoto
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  •  Hiroyuki Mizuguchi
    Graduate School of Pharmaceutical Sciences, Osaka University
  • CS1-1Development of functional enterocytes and hepatocytes by using regenerative medicine-derived techniques for pharmaceutical research
  • SpeakerHiroyuki Mizuguchi
    Graduate School of Pharmaceutical Sciences, Osaka University
  • CS1-2Development of delivery technology for genome editing therapy for muscular dystrophy
  • SpeakerAkitsu Hotta
    CiRA, Kyoto University
  • CS1-3The principle and applications of STED microscopy
  • SpeakerHiroshi Kawabe
    Department of Pharmacology, Gunma University Graduate School of Medicine
  • CS1-4Structural dynamics and drug interactions of P-glycoprotein
  • SpeakerTakeshi Murata
    Graduate School of Science, Chiba University

Special Symposium 2

November 9 (Wed.) 13:00-15:30 Room C (3F 311+312)

What are Exosomes?
-Extracellular Vesicles: from bench to clinical application-

  • ChairsMasaaki Kakehi
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  •  Kentaro Otake
    Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited
  • CS2-1Exosome engineering for biomedical applications
  • SpeakerKazunari Akiyoshi
    Graduate School of Engineering, Kyoto University
  • CS2-2Analysis of pharmacokinetics of exosomes and therapeutic application of exosomes
  • SpeakerYuki Takahashi
    Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University
  • CS2-3Development of cancer diagnostic and therapeutic methods by targeting exosomes
  • SpeakerYusuke Yoshioka
    Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University
  • CS2-4Utilization of extracellular vesicles in neuroscience drug discovery
  • SpeakerKentaro Otake
    Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited

Special Symposium 3

November 10 (Thu.) 9:00-11:30 Room D (4F 411+412)

IQ Consortium Symposium
-Advance Drug Research and Clinical Development to Patients-

  • ChairsAkihiro Hisaka
    Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University
  •  Yuu Moriya
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  • CS3-1Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: An industry perspective
  • SpeakerMasakatsu Kotsuma
    Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd.
  • CS3-2In Vitro to In Vivo Correlations of Transporter Based Drug-Drug Interactions: Learnings from IQ Transporter Working Group Data Collection Project
  • SpeakerKimio Tohyama
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  • CS3-3Evaluation of PBPK Models for Organ-Impaired Populations
  • SpeakerSheila Annie Peters
    Boehringer Ingelheim Pharma GmbH & Co.
  • CS3-4Use of PBPK modeling for predicting drug-food interactions -an industry perspective」
  • SpeakersArian Emami Riedmaier
    Certara
  •  Kesisoglou, Filippos
    MSD

Special Symposium 4

November 10 (Thu.) 13:00-15:30 Room A (3F 315)

The in vitro BBB model in Japan
-State-of-the art technology & Future perspective-

  • ChairsHiroyuki Kusuhara
    Graduate School of Pharmaceutical Sciences, the University of Tokyo
  •  Shinji Iwasaki
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  • CS4-1Development of advanced human blood-brain barrier models that facilitate characterization of brain penetration properties of CNS drugs
  • SpeakerTomomi Furihata
    Laboratory of Clinical Pharmacy & Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • CS4-2A breakthrough in drug discovery by new technology of in vitro human BBB models
  • SpeakerYukio Takeshita
    Blood-Brain Barrier Research Center, Yamaguchi University Graduate School of Medicine/ Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate school of Medicine
  • CS4-3Development of human iPS cell derived-brain microvascular endothelial cells in the BBB model for application in drug development
  • SpeakerTadahiro Hashita
    Graduate School of Pharmaceutical Sciences, Nagoya City University
  • CS4-4In vitro BBB model and drug development
  • SpeakerKenji Kawabata
    Laboratory of Cell Model for Drug Discovery, National Institutes of Biomedical Innovation, Health, and Nutrition
  • CS4-5Blood-Brain Barrier In Vitro Models with Open Networks for Screening of Receptor-Mediated Transport
  • SpeakerMichiya Matsusaki
    Graduate School of Engineering, Osaka University

Special Symposium 5

November 10 (Thu.) 13:00-15:30 Room B (3F 313+314)

Future perspective of "Tissue clearing technology" for evaluation of biodistribution.

  • ChairsSyunsuke Yamamoto
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
  •  Sohei Nakayama
    MiltenyiBiotec K.K.
  • CS5-1Cell-type-specific transduction in mouse CNS using blood-brain-barrier-penetrating AAV vector
  • SpeakerAyumu Konno
    Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine
  • CS5-2Investigation of neural circuits controlling hibernation using whole-mount imaging of optically cleared brain
  • SpeakerHiroshi Yamaguchi
    Research Institute of Environmental Medicine, Nagoya University
  • CS5-3Development of Advanced Imaging and Diagnostic Techniques Based on Quantum Nano-Optics for Pharmacokinetics
  • SpeakerHiroshi Yukawa
    Institute for Quantum Life Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology / Institute of Nano-Life-Sciences, Institutes of Innovation for Future Society, Nagoya University
  • CS5-4Cutting-edge methodology for biodistribution evaluation opened up by recent advances in tissue clearing and light-sheet microscopy
  • SpeakerSyunsuke Yamamoto
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Toxicology Session

November 10 (Thu.) 13:00-15:30 Room F (4F 418)

Interface between toxicology and DMPK

  • ChairsTadahiro Shinozawa
    Research, Takeda Pharmaceutical Company Limited
  •  Kosei Ito
    Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University
  • TS-1Consideration of Species differences in Drug-metabolism on Genotoxicity Assessment
  • SpeakerNaoki Koyama
    Global Drug Safety, Eisai Co., Ltd.
  • TS-2Drug-induced convulsion liability assessment using in vitro primary rat cortical neurons – comparison with in vivo convulsion model –
  • SpeakerYuki Seki
    Global Drug Safety, Eisai Co., Ltd.
  • TS-3Proposals for predicting drug efficacy/safety based on the estimation of intracellular concentrations; from the perspective of in vitro experiments- and modeling-based pharmacokinetic analyses
  • SpeakerTakashi Yoshikado
    Yokohama University of Pharmacy
  • TS-4Where does modeling lead pharmacology and pharmacotherapy?
  • SpeakerAkihiro Hisaka
    Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University

Symposium 1 (New Modality DIS 1)

November 9 (Wed.) 9:00-11:30 Room A (3F 315)

Pharmacokinetic research to navigate the development of oligonucleotide therapeutics

  • ChairsMakiya Nishikawa
    Faculty of Pharmaceutical Sciences, Tokyo University of Science
  •  Masataka Oitate
    Group IV, Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
  • SY1-1Regulation and regulatory science on pharmacokinetics of oligonucleotide therapeutics
  • SpeakerYoshiro Saito
    Division of Medicinal Safety Science, National Institute of Health Sciences
  • SY1-2Pharmacokinetics assessment of oligonucleotides in Nippon Shinyaku
  • SpeakerShunji Imai
    Pharmacokinetics and Safety Assessment Department, Discovery Research Laboratories, Nippon Shinyaku Co., Ltd.
  • SY1-3DDS study on regulation of pharmacokinetics of nucleic acids
  • SpeakerMakoto Oba
    Graduate School of Medical Science, Kyoto Prefectural University of Medicine
  • SY1-4Study of supporting drug discovery and drug development of a new modality agent by 2-dimensional to 3-dimensional imaging pharmacokinetic analysis using high-intensity fluorescence-labeled probes
  • SpeakerAkinobu Hamada
    Fundamental Innovative Oncology Core, National Cancer Center Research Institute

Symposium 2 (Drug Efficacy and Safety DIS)

November 9 (Wed.) 9:00-11:30 Room B (3F 313+314)

Utilisation of digital analytics technology for preventive and therapeutic medicine

  • ChairsSatoru Koyanagi
    Kyushu University, Faculty of Pharmaceutical Sciences
  •  Masanori Tachikawa
    Tokushima University, Institute of Biomedical Sciences
  • SY2-1Data-driven drug discovery and healthcare by AI
  • SpeakerYoshihiro Yamanishi
    Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology
  • SY2-2Prediction model for anticancer drug sensitivity using machine learning
  • SpeakerMasashi Honma
    Department of Pharmacy, The University of Tokyo Hospital
  • SY2-3Development of preventive methods to treat anticancer drug–induced adverse reactions using digital analysis technology on large-scale medical information databases
  • SpeakerYoshito Zamami
    Department of Pharmacy, Okayama University Hospital
  • SY2-4Personalized health management system by chronobiology and chrono-nutrition
  • SpeakerYu Tahara
    Graduate School of Biomedical and Health Sciences, Hiroshima University

Symposium 3 (Drug Metabolism and Drug Induced Toxicity DIS 1)

November 9 (Wed.) 9:00-11:30 Room C (3F 311+312)

Recent Progress in Detection Methods and Toxicity Assessment of Reactive Metabolites of Carboxyl Group-containing Drugs

  • ChairsKouichi Yoshinari
    Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka
  •  Takahito Nishiyama
    Department of Drug Metabolism and Molecular Toxicology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • SY3-1Characterization of enzymes determining the formations of acyl-glucuronidation and acyl-CoA conjugates
  • SpeakerTatsuki Fukami
    Faculty of Pharmaceutical Sciences, Kanazawa University
  • SY3-2Detection of acyl glucuronide-peptide adducts using dansylated Lys-Phe and its application to toxicity evaluation
  • SpeakerAtsushi Iwamura
    DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
  • SY3-3Toxicity of acyl glucuronides and risk assessment - cysteine adduct detection
  • SpeakerHiroshi Harada
    Drug Metabolism and Pharmacokinetics Research Lab., Kissei Pharmaceutical Co., LTD.
  • SY3-4Bioactivation of diclofenac mediated by P450/UGT and the possible target proteins identified in human hepatocytes
  • SpeakerKazuko Inoue
    Eisai Deep Human Biology Learning Medicine Development Biopharmaceutical Assessment Function Unit Global DMPK
  • SY3-5Investigation of the trapping assay for reactive acyl CoA metabolites and their risk assessment
  • SpeakerNobuyuki Kakutani
    Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc.

Symposium 4 (Modeling & Systems Pharmacology DIS)

November 9 (Wed.) 9:00-11:30 Room D (4F 411+412)

Compass for the future of Physiologically Based Pharmacokinetic Modelling

  • ChairsMasayo Oishi
    Systems Pharmacology, Non-Clinical Biomedical Science, Applied Research & Operations, Astellas Pharma Inc.
  •  Ryoko Sawamura
    Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd.
  • SY4-1Developing a robust QSP model of AAV based gene therapy for clinical applications
  • SpeakerNessy Tania
    Quantitative Systems Pharmacology, Early Clinical Development, Pfizer Worldwide Research, Development and Medical
  • ChairsTakayo Ueno
    Bristol Myers Squibb
  •  Yasuhisa Nagasaka
    Non-Clinical Biomedical Science, Applied Research & Operations, Astellas Pharma Inc.
  • SY4-2Application of Physiologically Based Pharmacokinetic (PBPK) Modeling towards Discovery and Development of Cellular Therapies
  • SpeakerAman P. Singh
    Clinical Pharmacology and Modeling, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Development Center Americas, Cambridge MA
  • ChairsYuki Iwaki
    Janssen Pharmaceutical Companies of Johnson & Johnson
  •  Koji Chiba
    Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy
  • SY4-3Mechanistic Considerations for Clinical-Translational GalNAc-siRNA Development: Insights from Minimal Physiologically-based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Modeling
  • SpeakerVivaswath S. Ayyar
    Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, LLC, USA
  • ChairsTsuyoshi Minematsu
    Immuno-Oncology, Astellas Pharma Inc.
  •  Shinichi Kijima
    Office of New Drug V/ Office of New Drug IV, Pharmaceuticals and Medical Devices Agency
  • SY4-4Physiologically-Based Pharmacokinetic Modelling for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
  • SpeakerHannah M Jones
    Certara UK Limited, Simcyp Division, Level 2-Acero
  • ChairsRyosei Kawai
    Chuo Translational Science LLC
  •  Teruki Hamada
    Discovery DMPK and Toxicology, Integrated & Translational Science, Axcelead Drug Discovery Partners, Inc.
  • SY4-5Challenge of exploratory use of physiologically based pharmacokinetic model
  • SpeakerKoji Chiba
    Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy

Symposium 5 (Absorption DIS)

November 9 (Wed.) 9:00-11:30 Room G (4F 419)

DRUG ABSORPTION FROM ZERO: The Deep Truth of Oral Drug Absorption Viewed from the Perspective of API/Drug Product
-From the Basics to the State-of-the-Art for Precision Drug Development-

  • ChairsYoshiyuki Shirasaka
    Faculty of Pharmacy, Kanazawa University
  •  Naomi Wakayama
    Eisai Co., Ltd.
  • SY5-1Pharmacokinetic Perspective: Quantitative analysis of the impact of special formulation on nonlinear gastrointestinal absorption
  • SpeakerYoshiyuki Shirasaka
    Faculty of Pharmacy, Kanazawa University
  • SY5-2Pharmaceutical Perspective: considering the drug concentration in the GI tract
  • SpeakerShinji Yamashita
    Faculty of Pharmaceutical Sciences, Setsunan University
  • SY5-3Formulation Perspective: Bioperformance assessment and Bioequivalence assurance
  • SpeakerYasuhiro Tsume
    MSD
  • SY5-4Regulatory perspectives: Permeability assessment in Biopharmaceutics Classification System-based biowaivers
  • SpeakerHideaki Kuribayashi
    Office of New Drug I, Pharmaceuticals and Medical Devices Agency (PMDA)

Symposium 6 (Microphysiological system and iPS DIS)

November 10 (Thu.) 9:00-11:30 Room A (3F 315)

How should the cellular and organ models for MPS functionality be?

  • ChairsSeiichi Ishida
    Sojo University
  •  Hiroyuki Mizuguchi
    Graduate School of Pharmaceutical Sciences, Osaka University
  • SY6-1Ideal cell and organ models from Pharma’s views- Case of AMED-MPS PJ-
  • SpeakerHitoshi Naraoka
    Applied Research & Operations, Astellas Pharma Inc.
  • SY6-2Case report of device evaluation tests by pharmaceutical companies in AMED-MPS
  • SpeakerHiroyuki Moriguchi
    Non-Clinical Biomedical Science, Astellas Pharma Inc.
  • SY6-3Development of human placenta models
  • SpeakerHirokazu Kaji
    Tokyo Medical and Dental University
  • SY6-4Human induced pluripotent stem cell-derived blood–brain barrier model for microphysiological system
  • SpeakerYoshiharu Deguchi
    Faculty of Pharma-Sciences, Teikyo University
  • SY6-5iPS cell-derived intestinal cells for evaluation of the intestinal absorption and safety of drugs
  • SpeakerTakahiro Iwao
    Graduate School of Pharmaceutical Sciences, Nagoya City University
  • SY6-6Development of liver-on-a-chips for pharmacokinetic and toxicity testing
  • SpeakerKazuo Takayama
    Center for iPS Cell Research and Application, Kyoto University

Symposium 7 (BioAnalysis and BioImaging DIS)

November 10 (Thu.) 9:00-11:30 Room B (3F 313+314)

Biotransformation of Therapeutic Antibodies and Application to Drug Discovery

  • ChairsMasamitsu Maekawa
    Graduate School of Pharmaceutical Sciences, Tohoku University
  •  Junji Komaba
    Ono Pharmaceutical Co., Ltd
  • SY7-1Biotransformation of therapeutic antibodies in the body
  • SpeakerAtsushi Yonezawa
    Graduate School of Pharmaceutical Sciences, Kyoto University
  • SY7-2Biotransformation evaluation of therapeutic monoclonal antibody using LC- MS
  • SpeakerKazuhiro Kobayashi
    Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division, Kyowa Kirin Co. Ltd.
  • SY7-3Bioanalytical approaches to evaluate in vivo behavior of ADCs
  • SpeakerHideo Takakusa
    Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi-Sankyo Co., Ltd
  • SY7-4Immunogenicity evaluation system using LC/MS (MAPPs) for therapeutic antibodies
  • SpeakerNobuo Sekiguchi
    Discovery Biologics Dept., Chugai Pharmaceutical Co., Ltd.

Symposium 8 (New modality DIS 2)

November 10 (Thu.) 9:00-11:30 Room C (3F 311+312)

Up-to-date pharmacokinetic studies for gene therapy products

  • ChairsTakashi Kuwabara
    Laboratory of Biologics evaluation,Yokohama University of Pharmacy
  •  Yoichi Naritomi
    Healios K.K.
  • SY8-1Biodistribution, PK/PD and Related Analytical Considerations for AAV Gene Therapy
  • SpeakerShigeru Takeshita
    Clinical Pharmacology & Exploratory Development – Oncology, Astellas Pharma Inc.
  • SY8-2Clinical pharmacology evaluation of Zolgensma
  • SpeakerOkishi Mashita
    PK Sciences Japan, Translational Medicine, Novartis Pharma K.K.
  • SY8-3Development of a replication-incompetent adenovirus vector and oncolytic adenovirus containing microRNA-mediated post-transcriptional de-targeting system
  • SpeakerFuminori Sakurai
    Graduate School of Pharmaceutical Sciences, Osaka University
  • SY8-4Evaluation methods of biodistribution and safety of gene therapy products
  • SpeakerMasafumi Onodera
    Gene & Cell Therapy Promotion Center, National Center for Child Health and Development

Symposium 9 (Drug Metabolism and Drug Induced Toxicity DIS 2)

November 10 (Thu.) 9:00-11:30 Room F (4F 418)

Integrated understanding of functions of drug metabolism in the brain

  • ChairsSeigo Sanoh
    School of Pharmaceutical Sciences, Wakayama Medical University
  •  Tetsuya Nakagawa
    Preclinical Research Unit, Sumitomo Pharma Co., Ltd.
  • SY9-1Cytochrome P450 enzymes in the brain
  • SpeakerToshiro Niwa
    School of Pharmacy, Shujitsu University
  • SY9-2Role of bioactive lipids produced by drug-metabolizing enzymes in the brain
  • SpeakerAmi Oguro
    Graduate School of Biomedical and Health Sciences, Hiroshima University
  • SY9-3Synthetic cannabinoids elicit elevation of endogenous cannabinoids: mechanism and the effect on learning and memory
  • SpeakerYuji Ishii
    Graduate School of Pharmaceutical Sciences, Kyushu University
  • SY9-4Potential of the Imaging Mass Spectrometry to understand the metabolism and distribution in brain
  • SpeakerKenichi Watanabe
    Preclinical Research Unit, Sumitomo Pharma Co., Ltd.
  • SY9-5Drug discovery research for anti-Parkinson's agents based on oxicam anti-inflammatory drugs
  • SpeakerTomoyuki Ohe
    Faculty of Pharmacy, Keio University

Symposium 10 (Transporter DIS)

November 10 (Thu.) 9:00-11:30 Room G (4F 419)

Future perspectives in transporter-driven drug development

  • ChairsKatsuhisa Inoue
    Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  •  Naoki Ishiguro
    Pharmacokinetic and Non-Clinical Safety, Nippon Boehringer Ingelheim Co., Ltd.
  • SY10-1Novel approach for cancer therapy by simultaneous targeting of xCT-dependent cystine transport and aldehyde dehydrogenase activity
  • SpeakerOsamu Nagano
    School of Medicine Institute for Advanced Medical Research (Division of Gene Regulation), Keio University
  • SY10-2High-throughput screening technology for drug discovery research of membrane proteins and its applications ~transporters, claudins, etc.~
  • SpeakerTakashi Motoyaji
    SEEDSUPPLY INC.
  • SY10-3Receptor-mediated transport for delivery of macro- and middle-molecular drug across biological barriers
  • SpeakerSumio Ohtsuki
    Faculty of Life Sciences, Kumamoto University
  • SY10-4Activation of regulatory T cells through lactate transporter in the tumor environment
  • SpeakerSyohei Koyama
    Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center

Symposium 11 (DDS DIS)

November 10 (Thu.) 13:00-15:30 Room C (3F 311+312)

DDS technologies in therapeutic peptides and nucleic acids-development -Introduction of AMED project for DDS-

  • ChairsTatsuhiro Ishida
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
  •  Shigeru Kawakami
    Graduate School of Biomedical Sciences, Nagasaki University
  • SY11-1Design of charge-reversible lipid nanoparticles for nucleic acid delivery
  • SpeakerTomohiro Asai
    Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences
  • SY11-2Controlling immune system by lipid nanoparticle
  • SpeakerTakashi Nakamura
    Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University
  • SY11-3Study of polymeric micelles for delivery of nucleic acid, peptide, protein therapeutics
  • SpeakerNobuhiro Nishiyama
    Institute of Innovative Research, Tokyo Institute of Technology
  • SY11-4Non-invasive transdermal drug delivery system using S/O technology as an alternative to injection
  • SpeakerMasahiro Goto
    Transdermal Drug Delivery Research Center, Graduate School of Engineering, Kyushu University
  • SY11-5Polypeptide encapsulation and in vivo transportation analysis of hyaluronic acid nanogel and its vaccine application
  • SpeakerToru Katsumata
    New Product Development Office, Functional Additives Division, Asahi Kasei Corporation
  • SY11-6Ionic liquid-based transcutaneous delivery of macromolecules
  • SpeakerTaro Shimizu
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University

Symposium 12 (Regulation DIS)

November 10 (Thu.) 13:00-15:30 Room D (4F 411+412)

Drug-Drug Interactions: Latest trends on pharmacokinetic research including new modality and regulatory harmonization

  • ChairsNaomi Nagai
    Research Institute of Pharmaceutical Sciences, Musashino University
  •  Akihiro Ishiguro
    Office of Review Management, Pharmaceuticals and Medical Devices Agency
  • SY12-1Summary and future plans of ICH M12(Drug Interaction Studies)draft guideline
  • SpeakerMotohiro Hoshino
    Office of New Drug V, Pharmaceuticals and Medical Devices Agency
  • SY12-2Discussion Points in ICH M12 (Drug Interaction Studies) draft guideline for implementation in Drug Research and Development
  • SpeakerSo Miyoshi
    Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association/ Clinical Pharmacology, Pfizer R&D Japan
  • SY12-3Current Status of Nonclinical Drug Interaction Studies on Oligonucleotide Drug Candidates: Results of a Questionnaire Survey of Pharmaceutical Companies
  • SpeakerKei Fukuhara
    Task Force for DMPK Evaluation of Oligonucleotide Therapeutics, Japan Pharmaceutical Manufacturers Association/ Clinical Pharmacology, Pfizer R&D Japan
  • SY12-4Current Research Trends in Quantitative Prediction of Drug Interactions
  • SpeakerKazuya Maeda
    Kitasato University School of Pharmacy

Symposium 13 (Educational and Crosscutting DIS)

November 10 (Thu.) 13:00-15:30 Room G (4F 419)

Basic course of pharmacokinetics on cross-disciplinary

  • ChairsTamihide Matsunaga
    Graduate School of Pharmaceutical Sciences, Nagoya City University
  •  Takafumi Komori
    Biopharmaceutical Assessment Core Function Unit / Global DMPK, Eisai Co., Ltd.
  • SY13-1The contribution of non-cytochrome P450 enzymes to drug metabolism and in vitro/in vivo evaluation in drug development: contribution of aldehyde oxidase to drug metabolism
  • SpeakerSeigo Sanoh
    Laboratory of Pharmaceutical Health Science, School of Pharmaceutical Sciences, Wakayama Medical University
  • SY13-2Reactive metabolite assessment in drug discovery research
  • SpeakerMakoto Ozawa
    Discovery ADMET group, Pharmaceutical and biomedical research department, Daiichisankyo RD Novare Co.,Ltd.
  • SY13-3In vitro assays for transporter-mediated DDIs: principles and theoretical considerations
  • SpeakerYoshitane Nozaki
    Global DMPK, Eisai Co., Ltd.
  • SY13-4Prediction of human pharmacokinetics of food-derived compounds based on in vitro tests
  • SpeakerTakashi Kitaguchi
    Global Food Safety Institute, Nissin Foods Holdings Co., Ltd.

Asia Joint Symposium

November 9 (Wed.) 13:00-15:30 Room A (3F 315)

Brand-New Technologies to Open Up the Future of Drug Development

  • ChairKazuya Maeda
    Kitasato University School of Pharmacy
  • JSY-1CNS-targeted nanoDDS based on the nose-to-brain route
  • SpeakerTakanori Kanazawa
    Department of Pharmaceutical Engineering & Drug Delivery Sciences, School of Pharmaceutical Sciences, University of Shizuoka
  • JSY-2Pharmacometrics as a tool for optimization of dose regimens in malaria and cholangiocarcinoma
  • SpeakerKesera Na-Bangchang
    Chulabhorn International College of Medicine and Drug Discovery and Development Center, Thammasat University
  • JSY-3A novel integrated pharmacokinetic/pharmacodynamic model to assess combination therapy and application to anticancer drug synergism
  • SpeakerYoung Hee Choi
    College of Pharmacy, Dongguk University
  • JSY-4New therapeutic modality for liver diseases: from the metabolism regulation view
  • SpeakerHuichang Bi
    School of Pharmaceutical Sciences, Southern Medical University

The Predoctoral Researcher-Initiative Session (PRIS) 2022

November 9 (Wed.) 14:30-17:00 Room D (4F 411+412)

Further Development of Drug Discovery Innovations by Mutual Improvement of Next Generation Researchers

  • ChairsIori Azuma
    Laboratory of Molecular Pharmamacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo
  •  Wangyang Liu
    Graduate School of Pharmacy, Takasaki University of Health & Welfare
  • PSY-SLUtility of clinical pharmacokinetic information to establish reliable PBPK model parameters
  • SpeakerKenta Yoshida
    Clinical Pharmacology, Genentech Research and Early Development
  • PSY-1Drug delivery strategy via endocytic pathway exploiting lysosomal transporters
  • SpeakerRyuto Tomabechi
    Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • ChairsHiroki Sunakawa
    Graduate School of Pharmacy, Takasaki University of Health & Welfare
  •  Yuta Tamemoto
    Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University
  • PSY-2Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties
  • SpeakerTakayuki Oguma
    Graduate School of Pharmaceutical Sciences, University of Shizuoka
  • PSY-3Characteristics of enzymes catalyzing oxidation of an alcohol group of small compounds
  • SpeakerRei Sato
    Drug Metabolism and Toxicology, Graduate School of Pharmaceutical Sciences, Kanazawa University
  • ChairsMiyuki Takemura
    Membrane Transport and Biopharmaceutics, Graduate School, Division of Pharmacy, Kanazawa University
  •  Seiya Ohki
    Department of Clinical Pharmacy and Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • PSY-4Evaluation of the risks of EGFR tyrosine kinase inhibitor-induced diarrhea with cultured intestinal stem cells originated from crypts in monkeys and humans
  • SpeakerYoshiki Hashimoto
    Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • PSY-5Efficient adjuvant-free intranasal vaccine that harnesses previously induced antibodies as antigen-delivery carriers
  • SpeakerAtsushi Kawai
    Laboratory of Nano-Design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University

Chair's Session(Companies-Academia Young Exchange)

November 10 (Thu.) 9:00-11:30 Room E (4F 413)

Exchange event for young DMPK researchers in industry
<<Sailing to the Future from YOKOHAMA! >>

  • OrganizerHiroshi Mizuuchi
    DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
  • OrganizerHideki Hirabayashi
    Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited